All U.S. military veterans in suicidal crisis are now eligible for free care
Unlike for most other medical benefits, veterans do not have to be enrolled in the VA system to be eligible. More than 18 million veterans in the U.S. could be eligible.
Progress on mental health and addiction is real — and often underreported. This archive covers treatment breakthroughs, policy shifts, community-led programs, and research advances that are improving lives. It’s evidence that change is possible.
Unlike for most other medical benefits, veterans do not have to be enrolled in the VA system to be eligible. More than 18 million veterans in the U.S. could be eligible.
Psychedelic medicine just crossed a historic threshold — Australia is now the first country to give psychiatrists a legal pathway to prescribe psilocybin and MDMA as regulated treatments for PTSD and treatment-resistant depression. For patients who have cycled through every available option without relief, that’s a genuinely new door opening. The decision followed thousands of public submissions and a growing body of clinical evidence, including a landmark New Zealand Journal of Medicine study on psilocybin’s efficacy. It shows that political barriers — not just scientific ones — can eventually fall when evidence and public pressure align.\n\n—\n\n**Word count: 95**
In a study published in Pharmaceutics, scientists tested their vaccine on 60 rats. The immunized animals could produce antibodies that stop the deadly drug’s effects.
In tests performed on rats at the University of Houston, the vaccine was shown to be effective at keeping one of the deadliest street drugs from reaching the brain, while not producing any significant side effects.
Colorado’s Natural Medicine Health Act goes further than any previous U.S. state psychedelic law, removing criminal penalties for personal use of psilocybin, DMT, ibogaine, and mescaline — and building a licensed therapy clinic system alongside it. The FDA has already granted psilocybin “breakthrough therapy” status for treatment-resistant depression, giving this reform unusual clinical credibility. Colorado helped pioneer cannabis legalization in 2012, and advocates are watching to see whether psychedelic reform follows a similar path outward. For people who haven’t found relief through conventional treatments, this law opens a genuinely new door.
The age-adjusted prevalence of dementia declined from 12.2 percent of people over age 65 in 2000 to 8.5 percent of people over age 65 in 2016—a nearly one-third drop from the 2000 level, according to a new RAND Corporation study.
Recreational cannabis legalization in Germany would mark a significant shift for Europe’s largest economy — moving the country away from a prohibition model that its own health minister says has shown no clear results. The proposal would allow licensed shops and pharmacies to sell cannabis to adults, with age-based limits on potency designed to protect younger users. Because Germany sits at the heart of the E.U., its approach could reshape how other member states think about drug policy far more than smaller precedents have. This is what evidence-based reform looks like in practice.
City lawmakers have unanimously approved a measure calling for the decriminalization of psychedelics like psilocybin and ayahuasca.
At least nine states now allow students to take mental health days. Other states using less expensive solutions like in-class mediation, mindfulness exercises, and social-emotional training.
Some 4,000 prisoners serving jail time for cannabis-related crimes will soon be released and their criminal records for those offenses will be deleted.